Just a few weeks ago, Pharmacopeia Inc. sounded like it was giving up the ghost, announcing that its chemistry service business couldn't be sustained and that it was looking for a home for its drug discovery expertise through a joint venture, merger or acquisition. But it didn't take long for PCOP to turn around with an acquisition that will help it integrate both upstream and downstream: Eos Biotechnology Inc. will give PCOP an upstream target discovery capability and an entity with a product focus.

Now that it will be able to develop therapeutics against its own